Anita Kohli, MD
Assistant Professor
Department
Medicine (Phoenix)
Position
Assistant Professor
Publications
- Journal of hepatology
Dale Kelly, WED-151 Routine cholestasis genetic testing in patients with intrahepatic cholestasis of pregnancy reveals high prevalence of genetic variants of bile acid transport defects
80, p. S709 - S710 2024 - The American journal of gastroenterology
Leff Phillip, S3496 A Rare Case of Non-Cirrhotic Portal Hypertension Caused by Necrobiotic Xanthogranuloma
118:10S, p. S2296 - S2296 2023 - Open forum infectious diseases
Shapiro Adrienne E, Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Non-inferiority Clinical Trial 2023 - Journal of hepatology
Yuen Man-Fung, LBP-38 - Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
78, p. S125 - S125 2023 - Journal of hepatology
Alkhouri Naim, FRI-525 - The effects of a novel online app (Noom Weight) on weight loss and liver biomarkers in patients with NAFLD: a single arm proof-of-concept study
78, p. S828 - S828 2023 - Journal of hepatology
Alkhouri Naim, SAT-488 - LIVERFASt GP+ (GP+), a non-invasive blood testing for NAFLD staging, improves risk stratification of patients with indeterminate FIB-4 results
78, p. S711 - S711 2023 - Hepatology communications
Noureddin Mazen, Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+and 4 scores
7:5 2023 - Hepatology (Baltimore, Md.)
Chang Devon, Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis
77:2, p. 546 - 557 2023 - Clinical gastroenterology and hepatology
Lawitz Eric J., Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
21:1, p. 143 - 152.e3 2023 - Journal of hepatology
Alkhouri Naim, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
77:3, p. 607 - 618 2022 - Journal of hepatology
Noureddin Mazen, The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH
77, p. S427 2022 - The lancet. Gastroenterology & hepatology
Harrison Stephen A., Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
7:7, p. 603 - 616 2022 - Gastroenterology (New York, N.Y. 1943)
Leff Phillip, Tu1311: EXTERNAL VALIDATION OF THE AGILE3+ SCORE AS A PREDICTOR OF ADVANCED FIBROSIS IN A COHORT OF U.S. ADULTS WITH BIOPSYPROVEN NAFLD
162:7, p. S-1271 2022 - The American journal of gastroenterology
Harrison Stephen A., Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
116:12, p. 2399 - 2409 2021 - Nature communications
Harrison Stephen A., A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
12:1, p. 5503 - 5503 2021 - American journal of preventive cardiology
Baum Seth J., LIVRQNac (AXA1125) ENHANCES INSULIN SENSITIVITY IN PRIMARY HUMAN HEPATOCYTES AND IN SUBJECTS WITH NAFLD AND T2D
7, p. 100263 2021 - Hepatology communications
Younossi Zobair M., Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
5:7, p. 1201 - 1211 2021 - Diabetes (New York, N.Y.)
Baum SETH, 752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D
70:Supplement_1 2021 - Hepatology (Baltimore, Md.)
Loomba Rohit, Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
73:2, p. 625 - 643 2021 - Gastroenterology (New York, N.Y. 1943)
Harrison Stephen A., Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
160:1, p. 219 - 231.e1 2021 - Hepatology (Baltimore, Md.)
Alkhouri Naim, Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic
72:5, p. 1509 - 1513 2020 - The American journal of gastroenterology
Aggarwal Pankaj, S1025 The Effects of Age on the Accuracy of the FAST Score to Predict the Presence of NASH With Significant Fibrosis
115:1, p. S522 - S522 2020 - The American journal of gastroenterology
Aggarwal Pankaj, S1024 Evaluation of the FAST Score in Patients With Nonalcoholic Fatty Liver Disease and High Liver Stiffness Measurements
115:1, p. S522 - S522 2020 - The American journal of gastroenterology
Aggarwal Pankaj, S3286 Identifying Patients With Metabolic Syndrome Who Require Pharmacotherapy for Nonalcoholic Steatohepatitis (NASH) Using the FAST Score
115:1, p. S1715 - S1715 2020 - The American journal of gastroenterology
Aggarwal Pankaj, S1190 Identifying Patients With Type 2 Diabetes Mellitus Who Require Pharmacotherapy for Nonalcoholic Steatohepatitis (NASH) Using the FAST Score
115:1, p. S595 - S595 2020 - Journal of hepatology
Harrison Stephen A., LBO01 - Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
73, p. S114 - S115 2020 - Journal of hepatology
Harrison Stephen A., LBP01 - Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (
73, p. S123 - S123 2020 - Journal of hepatology
Loomba Rohit, LBO04 - Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
73, p. S116 - S117 2020 - Liver international
Pockros Paul J., CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
39:11, p. 2082 - 2093 2019 - Open forum infectious diseases
Mera Jorge, Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives
6:7, p. ofz128 - ofz128 2019 - Hepatology communications
Shrivastava Shikha, Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus
2:12, p. 1451 - 1466 2018 - Journal of Viral Hepatitis
Shrivastava S., Augmentation of Hepatitis C Virus-Specific Immunity and Sustained Virologic Response
24:9, p. 742 - 749 2017 - Hepatology communications
Meissner Eric G., Rapid changes in peripheral lymphocyte concentrations during interferon‐free treatment of chronic hepatitis C virus infection
1:7, p. 586 - 594 2017 - Scientific reports
Nguyen Thi Huyen Tram, The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
7:1, p. 10233 - 10233 2017 - Journal of acquired immune deficiency syndromes (1999)
Wilson Eleanor, P-C8 Directly acting antiviral therapies have differential effects on cellular and soluble markers of inflammation in success-fully-treated HIV/HCV co-infected patients
74, p. 80 2017 - Journal of acquired immune deficiency syndromes (1999)
Rosenthal Elana, P-C13 Impact of HIV status, HCV genotype, and number of DAAs on HCV viral kinetics in patients with HCV genotype 1 receiving DAA therapy
74, p. 82 2017 - World journal of hepatology
Tang Lydia Shuk Yee, Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment
8:31, p. 1318 - 1326 2016 - Therapeutic advances in gastroenterology
Kohli Anita, Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease
9:6, p. 887 - 897 2016 - Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America
Kattakuzhy S., Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease
62:4, p. 440 - 447 2016 - Clinics in Liver Disease
Joshi Kartik, Alcoholic Liver Disease: High Risk Or Low Risk for Developing Hepatocellular Carcinoma?
20:3, p. 563 - 580 2016 - Hepatology international
Thornton Karla, Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment
10:4, p. 624 - 631 2016 - Journal of Viral Hepatitis
Meissner E. G., Achieving Sustained Virologic Response After Interferon-Free Hepatitis C Virus Treatment Correlates with Hepatic Interferon Gene Expression Changes Independent of Cirrhosis
23:7, p. 496 - 505 2016 - Gastroenterology (New York, N.Y. 1943)
Ruane Peter J., 756 Integrated Analysis of Sof+RBV or LDV/Sof for the Treatment of Genotype 4 Chronic HCV Infection
150:4, p. S1047 - S1048 2016 - Gastroenterology (New York, N.Y. 1943)
Flamm Steven, Su1423 Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/Sof) in Treatment-Experienced Cirrhotic Genotype 1 Patients With Chronic Hepatitis C (CHC): A Comparative Analysis of Gilead Sponsored Trials With 4 Real-World Cohorts (RWC)
150:4, p. S1095 - S1095 2016 - AIDS Research and Human Retroviruses
Townsend K., Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration
32:5, p. 456 - 462 2016 - Hepatology International
Petersen T., High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study
10:2, p. 310 - 319 2016 - Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America
Wilson E. M., Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens
62:3, p. 280 - 288 2016 - Clinical Advances in Hematology & Oncology
Kohli Anita, The Relationship between Hepatocellular Carcinoma and Hepatitis B and C Virus
14:2, p. 96 - 98 2016 - Expert review of anti-infective therapy
Nafisi Shirin, Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
14:1, p. 41 - 56 2016 - Journal of acquired immune deficiency syndromes (1999)
Kattakuzhy Sarah, P-B4 Predictors of sustained viral response to 4–6 week duration therapy with Ledipasvir + Sofosbuvir + Gs-9451 +/− Gs-9669 in early and advanced fibrosis (Nih-Ihv synergy trial)
71:Supplement 1, p. 73 2016 - Journal of acquired immune deficiency syndromes (1999)
Wilson Eleanor, P-B11 Retreatment of HCV GT-1 in patients who failed previous short course combination DAA therapy with 12 weeks of LDV/SOF is highly effective
71:Supplement 1, p. 77 2016 - AIDS (London, England)
Townsend K., Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir
30:2, p. 261 - 266 2016 - Annals of internal medicine
Kohli Anita, Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection
163:12, p. 899 2015 - The American journal of gastroenterology
Gill Kirat, A Case of IgG4-Related Disease: A Unique Presentation of a Rare Entity
110, p. S109 - S110 2015 - The American journal of gastroenterology
Khosla Manraj, Recurrent Post-partum Jaundice: Rare Genetic Disorder With Novel Genetic Mutations Identified
110, p. S397 2015 - The American journal of gastroenterology
Gane Edward, Ledipasvir/Sofosbuvir With or Without Ribavirin for the Treatment of Patients With Genotype 2-6 Chronic HCV Infection: Summary Results From Four Phase II Studies
110, p. S870 - S871 2015 - Open forum infectious diseases
Hahn Katherine J., Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment
2:3, p. ofv091 - ofv091 2015 - Clinical infectious diseases
Sidharthan Sreetha, Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials Reply
61:4, p. 667 - 668 2015 - The Lancet infectious diseases
Kohli Anita, Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof of Concept Phase 2a Cohort Study
15:9, p. 1049 - 1054 2015 - Clinical infectious diseases
Sidharthan Sreetha, Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy
60:12, p. 1743 - 1751 2015 - Journal of medical virology
Kohli Anita, Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse
87:4, p. 544 - 552 2015 - JAMA : the journal of the American Medical Association
Hogan John, Virologic response following combined ledipasvir and sofusbuvir administration in patients with HCV genotype 1 and HIV co-infection
313:12, p. 1232 2015 - The Lancet (British edition)
Kohli Anita, Directly Acting Triple Drug Anti-HCV Therapy Induces Sustained Virologic Response with a Six Week Regimen: A Proof of Concept Phase 2a Cohort Study
385:9973, p. 1107 - 1113 2015 - JAMA : the journal of the American Medical Association
Kohli Anita, Assessment of outcomes of hepatitis C treatment--reply
312:23, p. 2571 - 2571 2014 - Open forum infectious diseases
Meissner Eric, LB-4Changes in Intrahepatic, Endogenous Interferon Expression in Chronic HCV, Genotype-1 Patients Treated with Interferon-free, Ribavirin-Free DAA Regimens
1:suppl_1, p. S67 - S67 2014 - Annals of internal medicine
Osinusi Anu, Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse An Open-Label Pilot Study
161:9, p. 634 - U126 2014 - SpringerPlus
Kohli Anita, HCC surveillance results in earlier HCC detection: results from an Indian cohort
3:1, p. 1 - 5 2014 - JAMA : the journal of the American Medical Association
Kohli Anita, Treatment of Hepatitis C A Systematic Review
312:6, p. 631 - 640 2014 - AIDS research and human retroviruses
Shaffer Ashton, Short Communication: Serum-Based Assay Accurately Detects Single Nucleotide Polymorphisms of IL28B and SOCS3 in HIV/Hepatitis C Virus-Coinfected Subjects
30:8, p. 792 - 795 2014 - AIDS research and human retroviruses
Funk Emily K., Short Communication: Interferon/Ribavirin Treatment for HCV Is Associated with the Development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected Patients
29:9, p. 1190 - 1194 2013 - JAMA : the journal of the American Medical Association
Osinusi Anuoluwapo, Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics A Randomized Clinical Trial
310:8, p. 804 - 811 2013 - AIDS research and human retroviruses
Sherman Amy C., Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir
29:4, p. 665 - 672 2013 - Journal of acquired immune deficiency syndromes (1999)
Sidique Nadeera, HIV/HCV-Coinfected Natural Viral Suppressors Have Better Virologic Responses to PEG-IFN and Ribavirin Than ARV-Treated HIV/HCV Patients
58:2, p. E38 - E40 2011 - The American journal of tropical medicine and hygiene
Houpt Eric R, Short report : Asymptomatic Cryptosporidium hominis infection among human immundeficiency virus-infected patients in tanzania
73:3, p. 520 - 522 2005